Ipilimumab, a cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) inhibitor, has been approved by the US Food and Drug Administration to treat unresectable or metastatic melanoma. This evidence concerns the gene CTLA4 and metastatic melanoma.